(The Defender) There were “terrible flaws” in Moderna’s COVID-19 vaccine clinical trials — and the U.S. Food and Drug Administration (FDA) knew it, according to Alexandra Latypova, a former pharmaceutical industry executive who reviewed nearly 700 pages of documents Moderna submitted to the FDA as part of its application process.
Latypova, who has 25 years of experience in pharmaceutical research and development, started a number of successful companies — primarily focused on creating and reviewing clinical trials.
On a recent episode of “RFK Jr. The Defender Podcast,” she told Kennedy what she learned after reviewing the Moderna documents, obtained via a Freedom of Information Act request.
Latypova told Kennedy that out of nearly 700 pages, about 400 pages are irrelevant studies that Moderna repeated multiple times.
Moderna also submitted three versions of a single module, she said. And one module contained only narrative summaries of Moderna’s studies, but no actual study results.
“So we are still missing a large number of results, such as full reports that are supporting those narratives,” Latypova told Kennedy.
The FDA “obviously did not object” to any of this, she said. “That’s evidence of collusion to me with the manufacturer.”
Latypova also discussed Moderna’s clinical trials timeline. She said the Investigational New Drug (IND) application meeting is supposed to occur with the FDA when the company initiates human clinical trials.
